Lumibird (LBIRD) Q2 2026 TU earnings summary

Executive summary

• Consolidated revenue for H1 2026 reached €114.7 million, up 7.4% year-over-year and 9.7% on a like-for-like basis.

• Photonics division revenue surged 15.3% to €59.1 million, driven by Defense & Space, Medtech, and Industrial & Scientific segments.

• Medical division revenue was stable at €55.6 million, with growth resuming in Q2 after a disrupted Q1.

• High order backlog and strong momentum in key markets provide excellent visibility for future growth.

Financial highlights

• Q2 revenue grew 13.1% year-over-year, accelerating from 0.7% in Q1.

• Photonics Medtech segment posted the strongest growth at 58.3%, reaching €10.5 million.

• Americas region led growth in Photonics (+49.0%) and Medical (+5.4%).

• Asia-Pacific saw Photonics up 28.8% and Medical up 2.9%.

Outlook and guidance

• Confidence in continued profitable growth, supported by ramp-up of defense programs and high order backlog.

• Medical division expected to maintain positive momentum following Q2 recovery.